Hi all,
NICE are consulting on a new use of Enhertu in early breast cancer, and we need your help for our response
We’re looking for people with HER2 positive early breast cancer who received Enhertu (trastuzumab deruxtecan) as a neoadjuvant (before surgery) treatment as part of the Destiny-Breast11 clinical trial.
We’re also interested in talking to people who might have been eligible for it. To have been eligible for this drug, you would need to have been diagnosed with high-risk HER2-positive early stage breast cancer.
If you’re interested in getting involved, one of the members of our policy team would love to set up a call with you. This is a great opportunity to be able to share your views and have it directly inform our work regarding what treatments are available on the NHS.
This opportunity is separate from our current campaign Enhertu Now, which looks at the use of Enhertu for people with HER2-low metastatic breast cancer.
For more information please email policy@breastcancernow.org , we look forward to hearing from you!